Abstract
Although the efficacy of adding oxaliplatin(OX) to fluoropyrimidine (FU) plus bevacizumab (BEV) as initial therapy was shown in patients (pts) with metastatic colorectal cancer (MCRC), it is still uncertain in elderly pts. Therefore, we conducted a phase III trial to confirm the superiority of the addition of OX in terms of progression-free survival (PFS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
